Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1–34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.

Abstract: Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.

Abstract: This invention relates to an oral dosage form containing between 1 mg and 100 mg of memantine, wherein said dosage form does not contain 10 mg of memantine or 20 mg of memantine, and wherein said dosage form is not prepared by the patient or a person administering the drug to the patient who divides the dosage form containing a larger dose of memantine. Other aspects of this invention relate to pharmaceutical products comprising said dosage forms and methods of administering memantine and treating disease with said dosage form.

Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

Abstract: A dual-action latching device includes two vertical boards, a vertical moving latch, two horizontal poles, a horizontal fixed board, and two springs. Wherein the vertical moving latch of two sides board moves on the two vertical boards, that can impel the top latch or below latch to the cover, respectively, the two springs offer thrust to impel and orient one to slip horizontally and move on two horizontal poles again, and then the groove on imbedding and moving the latch vertically and slippery or putting the groove and orienting it, in order to be able to be used for fastening fixing it in the button trough of the host computer jointly separately.

Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Abstract: A cover positioning structure of a dual-usage portable computer is disclosed, which comprises a base, at least one slide block sliding on the base, at least one elastic slice imposing a pressure to the at least one slide block, and a rotary member rotated relative to the base. When rotated, a positioning protrusion of the rotary member is correspondingly positioned to a positioning recess of the at least one slide block. Therefore, the structure aforesaid not only achieves the positioning purpose of being damage-free, but also is cost-effective in having a minimum of elements and manufacture processes.

Abstract: A common lock used in a dual-usage portable computer formed of a base member and a display is disclosed to include a left-side hook and a right-side hook respectively pivoted to the base member on the inside, and an elongated operating frame bar axially slidably mounted inside the base member of the portable computer and coupled between the left-side hook and the right-side hook for operation by the user to bias the left-side hook and the right-side hook by means of a lever action and to further force the left-side hook and the right-side hook out of a respective through hole at the base member into engagement with a respective retaining block at the display to lock the display to the base member.

Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Abstract: A composition comprising a cyclodextrin, a guanidine-based cationic compound, and sorbic acid is disclosed herein. Preservatives and methods related thereto, and experimental results suggesting certain advantages related to these compositions, preservatives, and methods are also presented herein.

Abstract: A composition comprising a cyclodextrin, a guanidine-based cationic compound, and sorbic acid is disclosed herein. Preservatives and methods related thereto, and experimental results suggesting certain advantages related to these compositions, preservatives, and methods are also presented herein.

Abstract: Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.

Abstract: The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.

Abstract: This invention relates to an oral dosage form containing between 1 mg and 100 mg of memantine, wherein said dosage form does not contain 10 mg of memantine or 20 mg of memantine, and wherein said dosage form is not prepared by the patient or a person administering the drug to the patient who divides the dosage form containing a larger dose of memantine. Other aspects of this invention relate to pharmaceutical products comprising said dosage forms and methods of administering memantine and treating disease with said dosage form.

Abstract: A composition comprising a steroid, a cyclodextrin, and a polyhexamethylene biguanide is disclosed herein. Preservatives and methods related thereto, and experimental results suggesting certain advantages related to these compositions, preservatives, and methods are also presented herein.

Abstract: A disk ejection device of a portable computer and controlled method thereof, the disk ejection device includes a cover installed on a computer body of the portable computer, at least one torsional spring coupled between the computer body and the cover for providing a preliminary torque force to let the cover be in a closed state, and a controlled button disposed on the computer body for controlling a disk ejection thereby to push the cover. Furthermore, the prior optical disk drive can be replaced by the other optical disk drives with different size-designed front boards, and the portable computer still can have a good-looking appearance due to the cover.

Abstract: Disclosed herein are compositions comprising cyclodextrin derivatives and prednisolone and prodrugs thereof, and methods related thereto. The use of soluble polyanionic polymers such as hydroxypropylmethylcellulose and others in relation to these compositions is also disclosed. Delivery of these prednisolone-related compounds to the back of the eye via topical ophthalmic administration is also disclosed.

Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.

Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.